Evaluation of the Effect of Curcumin and Imatinib on BCR-ABL Expression Gene in Chronic Human k562 Cells

Gholamzadeh Virany, Zahra; Bagheri, Parisa; Hajebi Khaniki, Saeedeh; Chehreghani, Zahra; Rahimi, Hamid Reza

doi:10.18502/ijml.v9i2.10022

Write your message

ارسال به ایمیل

Volume 9, Issue 2 (May 2022) IJML 2022, 9(2): 141-149 | Back to browse issues page

‎ 10.18502/ijml.v9i2.10022

Mendeley

Zotero

RefWorks

Gholamzadeh Virany Z, Bagheri P, Hajebi Khaniki S, Chehreghani Z, Rahimi H R. Evaluation of the Effect of Curcumin and Imatinib on BCR-ABL Expression Gene in Chronic Human k562 Cells. IJML 2022; 9 (2) :141-149
URL: http://ijml.ssu.ac.ir/article-1-418-en.html

Evaluation of the Effect of Curcumin and Imatinib on BCR-ABL Expression Gene in Chronic Human k562 Cells

Zahra Gholamzadeh Virany

, Parisa Bagheri

, Saeedeh Hajebi Khaniki

, Zahra Chehreghani

, Hamid Reza Rahimi ^*

Vascular and Endovascular Surgery Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract: (522 Views)

Background and Aims: Detection of overexpression in tumor-inhibiting genes provides valuable information for leukemia diagnosis and prognosis. Chronic myeloid leukemia (CML) is a stem cell disorder determined by a well-defined genetic anomaly involving BCR-ABL translocation in the Philadelphia chromosome. Curcumin is a chemo-preventive agent for the primary cancer targets, such as the breast, prostate, lung, stomach, duodenum, colon cancers, and leukemias. Imatinib (Gleevec®, Glivec®) is a synthetic tyrosine kinase inhibitor that treats CML. This study aimed to investigate Curcumin and Imatinib's effect on K562, a human CML cell line that expresses p210 BCR-ABL.
Materials and Methods: In this study, Curcumin nanomicelles and Imatinib's apoptotic effects on the K562 cells and the expression of BCR-ABL were studied. BCR-ABL gene expression was evaluated using real-time polymerase chain reaction.
Results: The findings indicated a decrease in the desired gene expression, but the BCR-ABL gene expression of the samples treated with Curcumin nanomicelles did not differ significantly from Imatinib (group control). The amount fold change of the BCR-ABL gene for Imatinib and Curcumin nanomicelle was 0.497 and 0.540, respectively.
Conclusions: The present study showed that treating cellular category k562 with Curcumin nanomicelle and Imatinib reduces the BCR-ABL gene expression. Also, data showed that the Curcumin nanomicelle and Imatinib induced the apoptotic process.

Keywords: BCR-ABL gene, CML, Imatinib, k562 cells, Nano micelle Curcumin